{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T09:37:40Z","timestamp":1790933860672,"version":"4.1.0"},"reference-count":33,"publisher":"SAGE Publications","issue":"12","license":[{"start":{"date-parts":[[2019,11,22]],"date-time":"2019-11-22T00:00:00Z","timestamp":1574380800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,11,22]],"date-time":"2019-11-22T00:00:00Z","timestamp":1574380800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Technology &amp; Therapeutics"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>We evaluated the erythropoietic effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, in type 2 diabetes patients with anemia of chronic kidney disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Nine diabetes patients were enrolled and administered 100\u2009mg canagliflozin once a day for 12 weeks. The patients received fixed doses of conventional antidiabetic drugs and renin-angiotensin system inhibitors for 8 weeks before enrollment; these drugs were continued during the study. Endpoints were changes in erythropoiesis parameters, including erythrocyte and reticulocyte count, hemoglobin, hematocrit, and serum erythropoietin (EPO) concentration from baseline to 12 weeks. All variables were measured every 2 weeks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Serum EPO concentration increased by 38 [15\u201362]% (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u20090.043) between baseline and 2 and 4 weeks. Reticulocyte count transiently increased at 2 weeks. Erythropoiesis occurred after 2 weeks of canagliflozin treatment. Erythrocyte count (from 386\u2009\u00b1\u200936\u2009\u00d7\u200910\n                      <jats:sup>4<\/jats:sup>\n                      \/\u03bcL to 421\u2009\u00b1\u200936\u2009\u00d7\u200910\n                      <jats:sup>4<\/jats:sup>\n                      \/\u03bcL;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u20090.0009), hemoglobin (from 11.8\u2009\u00b1\u20090.6\u2009g\/dL to 12.9\u2009\u00b1\u20091.1\u2009g\/dL;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u20090.0049), and hematocrit (from 37.1\u2009\u00b1\u20092.3% to 40.4\u2009\u00b1\u20093.2%;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u20090.002) increased from baseline to study completion. Although there were no significant changes in transferrin saturation, serum ferritin levels were decreased (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u20090.003).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Canagliflozin treatment led to an improvement in erythropoiesis in patients with impaired kidney function. The effect on erythropoiesis appeared to be due to an EPO production-mediated mechanism and might be independent of glycemic control; however, further studies are needed to clarify this since the present study had a small sample size and no comparator group.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/dia.2019.0212","type":"journal-article","created":{"date-parts":[[2019,8,6]],"date-time":"2019-08-06T10:46:03Z","timestamp":1565088363000},"page":"713-720","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":94,"title":["Canagliflozin Improves Erythropoiesis in Diabetes Patients with Anemia of Chronic Kidney Disease"],"prefix":"10.1177","volume":"21","author":[{"given":"Takashi","family":"Maruyama","sequence":"first","affiliation":[{"name":"Division of Nephrology, Hypertension and Endocrinology, Department of Internal Medicine, Nihon University School of Medicine, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Takashima","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Hypertension and Endocrinology, Department of Internal Medicine, Nihon University School of Medicine, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidetaka","family":"Oguma","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Hypertension and Endocrinology, Department of Internal Medicine, Nihon University School of Medicine, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Hypertension and Endocrinology, Department of Internal Medicine, Nihon University School of Medicine, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiko","family":"Ohno","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Hypertension and Endocrinology, Department of Internal Medicine, Nihon University School of Medicine, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Utsunomiya","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Hypertension and Endocrinology, Department of Internal Medicine, Nihon University School of Medicine, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Furukawa","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Hypertension and Endocrinology, Department of Internal Medicine, Nihon University School of Medicine, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ritsukou","family":"Tei","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Hypertension and Endocrinology, Department of Internal Medicine, Nihon University School of Medicine, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Abe","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Hypertension and Endocrinology, Department of Internal Medicine, Nihon University School of Medicine, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2019,11,22]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-014-3196-x"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.12266"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/MNH.0b013e32835a17ae"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.113.005081"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1097\/MNH.0000000000000187"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0054442"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504720"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.00071.2006"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12127"},{"key":"e_1_3_3_11_2","first-page":"ii1","article-title":"Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure","volume":"19","author":"Locatelli F","year":"2004","unstructured":"Locatelli F, , Aljama P, , Barany P, et al.: Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant, 2004; 19:ii1\u2013ii47.","journal-title":"Nephrol Dial Transplant"},{"key":"e_1_3_3_12_2","first-page":"S9","article-title":"KDOQI clinical practice guidelines and clinical recommendations for anemia in chronic kidney disease","volume":"47","author":"KDOQI; National Kidney Foundation","year":"2006","unstructured":"KDOQI; National Kidney Foundation: KDOQI clinical practice guidelines and clinical recommendations for anemia in chronic kidney disease. Am J Kidney Dis, 2006; 47:S9\u2013S145.","journal-title":"Am J Kidney Dis"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinchem\/18.6.499"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2008.12.034"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-2724"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.00543.2015"},{"key":"e_1_3_3_17_2","article-title":"Dapagliflozin, SGLT2 inhibitor, attenuates renal ischemia-reperfusion injury","volume":"11","author":"Chang YK","year":"2016","unstructured":"Chang YK, , Choi H, , Jeong JY, et al.: Dapagliflozin, SGLT2 inhibitor, attenuates renal ischemia-reperfusion injury. PLoS One, 2016; 11:e0158810.","journal-title":"PLoS One"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ASN.0000017223.49823.2A"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.00409.2012"},{"key":"e_1_3_3_20_2","first-page":"385","article-title":"Shift toward anaerobic glycolysis in the regenerating rat kidney","volume":"60","author":"Ash SR","year":"1970","unstructured":"Ash SR, , Cuppage FE: Shift toward anaerobic glycolysis in the regenerating rat kidney. Am J Pathol, 1970; 60:385\u2013402.","journal-title":"Am J Pathol"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2015020177"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI74997"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V71.2.524.524"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-115857"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60407-2"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2018.0169"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.14740\/jocmr2760w"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.00640114"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.00689.2014"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-0330"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2005070757"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0100777"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.ackd.2005.01.008"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1177\/1479164118782872"}],"container-title":["Diabetes Technology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/dia.2019.0212","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/dia.2019.0212","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/dia.2019.0212","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T18:18:20Z","timestamp":1777400300000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/dia.2019.0212"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,22]]},"references-count":33,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["10.1089\/dia.2019.0212"],"URL":"https:\/\/doi.org\/10.1089\/dia.2019.0212","relation":{},"ISSN":["1520-9156","1557-8593"],"issn-type":[{"value":"1520-9156","type":"print"},{"value":"1557-8593","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,22]]}}}